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MONO QUATERNARY AMMONIUM SALTS

glutamate release) from superfused rat brain slices. Nicotinic

AND METHODS FOR MODULATING
NEURONAL NICOTINIC ACETYLCHOLINE
RECEPTORS

receptors are located in the cell body and terminal areas of
these neurotransmitter systems. NIC facilitates neurotrans
mitter release from nerve terminals.
The structural and functional diversity of central nervous
system nicotinic receptors has stimulated a great deal of inter

This application claims bene?t of US. Provisional Appli
cation No. 60/814,423, ?led Jun. 16, 2006, Which is incorpo
rated herein by reference in its entirety.

est in developing novel, subtype-selective agonists and/or
antagonists. Some of these agonists are currently being evalu
ated in clinical trials for cognitive enhancement and neuro

protective effects, potentially bene?cial for disease states

IDENTIFICATION OF FEDERAL FUNDING

such as Alzheimer’s and Parkinson’s disease.

The present invention was supported by Grant NIH
Ul9DA017548 from the National Institutes of Health, and
therefore the government may have rights in the invention.

SUMMARY OF THE INVENTION

In one embodiment, compounds corresponding to the fol
lowing structure are provided.

FIELD OF THE INVENTION

The invention relates to monoquaternary ammonium salts

(1)

and their use in modulating nicotinic acetylcholine receptors.
20

BACKGROUND OF THE INVENTION

S(—)-nicotine (NIC) activates presynaptic andpostsynaptic
neuronal nicotinic receptors that evoke the release of neu

rotransmitters from presynaptic terminals and that modulate
the depolarization state of the postsynaptic neuronal mem

25

brane, respectively. Thus, nicotine produces its effect by
binding to a family of ligand-gated ion channels, stimulated
by acetylcholine (ACh) or nicotine Which causes the ion
channel to open and cations to ?ux With a resulting rapid

30

A1, A2, A3, A4, and A5 are independently selected from
nitrogen or carbon, provided that When nitrogen is present,

(millisecond) depolarization of the target cell.
Neuronal nicotinic receptors are composed of two types of
subunits, 0t and [3, and assemble as heteromeric receptors With
the general stoichiometry of 2a and 3[3 or as homomeric
receptors With 5a subunits. Nine subtypes of the ct subunit
(a2 to (x10) and three subtypes of the [3 unit ([32 to [34) are

the nitrogen does not have an R substituent attached.

R1, R2, R3, R4, and R5 are each independently selected
35

from the group consisting of hydrogen, alkyl, substituted

found in the central nervous system. The mo st common nico

alkyl, cycloalkyl, substituted cycloalkyl, alkenyl, substituted
alkenyl, alkynyl, substituted alkynyl, aryl, substituted aryl,

tinic receptor subtype in the brain is composed of two (x4 and

heterocycle, substituted heterocycle, halo, cyano, and nitro,

three [32 subunits, i.e., (x4[32. These subunits display different,
but overlapping, patterns of expression in the brain. Examples
of heteromeric receptor subtypes include (x4[32, (x3[32, (x3 [34,

40

or R1 and R2 or R2 and R3 together With the carbons to Which
they are attached independently form a three to eight-member

cycloalkane, substituted cycloalkane, cycloalkene, substi

(x6[32, (x40t5[32, (x60t5[32, (x40t6[32, (x4[32[34, (x3[32[34, and

tuted cycloalkene, aryl, substituted aryl, heterocycle With one

others. The predominant homomeric subtype includes (x7, but
other combinations have also been proposed.
For the most part, the actual subunit compositions and
stoichiometries of nicotinic receptors in the brain remain to
be elucidated. Thus, neuronal nicotinic receptor subtype
diversity originates from differences in the amino acid
sequence at the subunit level and from the multiple combina
tions of assemblies of subunits into functional receptor pro
teins, Which affords a Wide diversity of pharmacological

to three hetero atoms in the ring, or substituted heterocycle
With one to three hetero atoms in the ring.
Z1 is absent or is selected from the group consisting of

45

alkyl, substituted alkyl, cycloalkyl, substituted cycloalkyl,
alkenyl, substituted alkenyl, alkynyl, substituted alkynyl,
phenylene, substituted phenylene, alkoxy, and substituted

alkoxy.
50

speci?city.
In spite of the extensive diversity in neuronal nicotinic
receptor messenger RNA expression, only a limited number
of tools are available to study the pharmacology of native
receptors. Radioligands are used in many studies. [3H]NIC

55

60

methyllycaconitine (MLA), Which has high af?nity for the (x7
nicotinic receptor subtype. Nicotinic receptor subtypes can
be studied using functional assays, such as NIC-evoked neu

rotransmitter release (e.g., [3H]dopamine (DA) release, [3 H]
norepinephrine (NE) release, [3H]serotonin (5-HT) release,
[3 H] gamma-aminobutyric acid (GABA) release and [3 H]

and substituted alkoxy.
Z3 is selected from is selected from hydrogen, alkyl, sub

stituted alkyl, cycloalkyl, substituted cycloalkyl, alkenyl,
substituted alkenyl, alkynyl, substituted alkynyl, aryl, substi
tuted aryl, heterocycle, and substituted heterocycle.

appears to label the same sites in the brain as [3H]ACh. It has

been estimated that over 90% of [3H]NIC binding in the brain
is due to association With the heteromeric receptor that is
composed of a4 and [32 subunits. Also abundant in the central
nervous system are the homomeric receptors labeled by [3 H]

Z2 is selected from the group consisting of alkyl, substi

tuted alkyl, cycloalkyl, substituted cycloalkyl, alkenyl, sub
stituted alkenyl, alkynyl, substituted alkynyl, arylene, substi
tuted arylene, heterocycle, substituted heterocycle, alkoxy,

65

X‘ is an inorganic or organic anion.
In another embodiment, a composition is provided com
prising a pharmaceutically acceptable carrier and a com
pound as described above.
In another embodiment, a method is provided for selec

tively modulating the function of a nicotinic acetylcholine
receptor comprising administering a therapeutically effective
amount of a compound as described above to a mammalian

subject in need thereof.

US 8,846,937 B2
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In another embodiment, a method is provided for prevent

The terms “disorder,” “disease,” and “condition” are used
inclusively and refer to any status deviating from normal.
The term “central nervous system associated disorders”

ing and/ or treating a central nervous system associated disor

der comprising administering a therapeutically effective
amount of a compound as described above to a mammalian

subject in need thereof.
In another embodiment, a method is provided for prevent
ing and/or treating substance use and/or abuse comprising

5

such as disorders associated with the alteration of normal
neurotransmitter release in the brain.
The term “lower alkyl” refers to straight or branched chain
alkyl radicals having in the range of l to 4 carbon atoms.
The term “alkyl” refers to straight or branched chain alkyl
radicals having 1 to 19 carbon atoms, and “substituted alkyl”

administering a therapeutically effective amount of a com

pound as described above to a mammalian subject in need
thereof.

In another embodiment, a method is provided for prevent

refers to alkyl radicals further bearing one or more substitu

ing and/or treating gastrointestinal tract disorders comprising

ents including, but not limited to, hydroxy, alkoxy (of a lower

administering a therapeutically effective amount of a com

alkyl group), mercapto (of a lower alkyl group), aryl, hetero
cyclic, halogen, tri?uoromethyl, cyano, nitro, amino, car
boxyl, carbamate, sulfonyl, and sulfonamide.

pound as described above to a mammalian subject in need
thereof.

Other methods, features and advantages of the present

The term “cycloalkyl” refers to cyclic ring-containing moi

invention will be or become apparent to one with skill in the

art upon examination of the following detailed descriptions. It
is intended that all such additional methods, features and
advantages be included within this description, be within the
scope of the present invention, and be protected by the accom

eties containing 3 to 8 carbon atoms, and “substituted
cycloalkyl” refers to cycloalkyl moieties further bearing one
20 or more substituents as set forth above.

The term “alkenyl” refers to straight or branched chain
hydrocarbyl groups having at least one carbon-carbon double
bond and having 2 to 19 carbon atoms, and “substituted
alkenyl” refers to alkenyl groups further bearing one or more

panying claims.
DETAILED DESCRIPTION OF THE INVENTION

includes any cognitive, neurological, and mental disorders
causing aberrant or pathological neural signal transmission,

25

substituents as set forth above.

The term “alkynyl” refers to straight or branched chain

hydrocarbyl moieties having at least one carbon-carbon triple
bond and having 2 to 19 carbon atoms, and “substituted
alkynyl” refers to alkynyl moieties further bearing one or

Before the present compositions and methods are
described, it is to be understood that the invention is not

limited to the particular methodologies, protocols, assays,
and reagents described, as these may vary. It is also to be
understood that the terminology used herein is intended to

30 more substituents as set forth above.

The term “aryl” refers to aromatic groups having 6 to 24

describe particular embodiments of the present invention, and

carbon atoms, and “substituted aryl” refers to aryl groups

is in no way intended to limit the scope of the present inven
tion as set forth in the appended claims.
It must be noted that as used herein and in the appended

further bearing one or more substituents as set forth above.

The term “heterocyclic” refers to cyclic moieties contain
35

ing one or more heteroatoms as part of the ring structure and

claims, the singular forms “a,” “an,” and “the” include plural

having 3 to 24 carbon atoms, and “substituted heterocyclic”

references unless the context clearly dictates otherwise.
Unless de?ned otherwise, all technical and scienti?c terms
used herein have the same meanings as commonly under
stood by one of ordinary skill in the art to which this invention
belongs. All publications cited herein are incorporated herein

refers to heterocyclic moieties further bearing one or more
substituents as set forth above.
40

de?ned above, polymers arrived at by de?ning substituents
with further substituents to themselves (e.g. substituted aryl

by reference in their entirety for the purpose of describing and

having a substituted aryl group as a substituent which is itself
substituted with a substituted aryl group, etc.) are not
intended for inclusion herein. In such cases, the maximum
number of such substituents is three. That is to say that each

disclosing the methodologies, reagents, and tools reported in
the publications that might be used in connection with the
invention. Nothing herein is to be construed as an admission

that the invention is not entitled to antedate such disclosure by

of the above de?nitions is constrained by a limitation that, for
example, substituted aryl groups are limited to -substituted

virtue of prior invention.
The term “nicotinic acetylcholine receptor” refers to the

aryl-(substituted aryl)-substituted aryl.

endogenous acetylcholine receptor having binding sites for
acetylcholine which also bind to nicotine. The term “nicotinic

The term “halogen” refers to ?uoride, chloride, bromide or
iodide groups. It is understood that in all substituted groups

Compounds of the present invention are mono quaternary
50

ammonium salts corresponding to Formula (I):

acetylcholine receptor” includes the term “neural nicotinic

acetylcholine receptor.”
The terms “subtype of nicotinic acetylcholine receptor,”
and “nicotinic acetylcholine receptor subtype” refer to vari
ous subunit combinations of the nicotinic acetylcholine
receptor, and may refer to a particular homomeric or hetero
meric complex, or multiple homomeric or heteromeric com

(1)
55

plexes.
The term “agonist” refers to a substance which interacts
with a receptor and increases or prolongs a physiological

60

response (i.e. activates the receptor).
The term “partial agonist” refers to a substance which
interacts with and activates a receptor to a lesser degree than
an agonist.
The term “antagonist” refers to a substance which interacts
with and decreases the extent or duration of a physiological

response of that receptor.

65

A1, A2, A3, A4, and A5 are independently selected from
nitrogen or carbon, provided that when nitrogen is present,
the nitrogen does not have an R substituent attached.

US 8,846,937 B2
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R1, R2, R3, R4, and R5 are each independently selected

benzoxazole, anthranil naphthalene, tetralin, decalin,
chromene, coumarin, chroman-4-one, isocoumarin, isoch
romen-3 -one, quinoline, isoquinoline, cinnoline, quinazo

from the group consisting of hydrogen, alkyl, substituted

alkyl, cycloalkyl, substituted cycloalkyl, alkenyl, substituted
alkenyl, alkynyl, substituted alkynyl, aryl, substituted aryl,

line, naphthyrdine, pyrido[3 ,4-b] -pyridine, pyridol [3 ,2-b]py
ridine, pyrido[4,3,-b]-pyridine, benzovaine, anthracene,
phenanthrene, phenalene, ?uorene, carazole, xanthene, acni
dine, octahydro-[l]pyridine, l-methyloctahydro-[l]pyrdine,
octahydroindole, l-methyloctahydro-indole, octahydro-cy
clopenta[b]pyrrole, l-methyloctahydro-cyclopenta[b]pyr

heterocycle, substituted heterocycle, halo, cyano, and nitro,
or R1 and R2 or R2 and R3 together With the carbons to Which
they are attached independently form a three to eight-member

cycloalkane, substituted cycloalkane, cycloalkene, substi
tuted cycloalkene, aryl, substituted aryl, heterocycle With one
to three hetero atoms in the ring, or substituted heterocycle
With one to three hetero atoms in the ring.
Z1 is absent or is selected from the group consisting of

role, decahydroquinoline, or l-methyldecahydroquinoline.
As a further example, heterocycles formed by A1, A2, A3,
A4, and A5 in combination With R1, R2, R3 , R4, and R5 include

alkyl, substituted alkyl, cycloalkyl, substituted cycloalkyl,
alkenyl, substituted alkenyl, alkynyl, substituted alkynyl,
phenylene, substituted phenylene, alkoxy, and substituted

pyridine, quinoline, 5,6,7,8-tetrahydroquinoline, isoquino
line, tetrahydroisoquinoline, pyraZine, pyrimidine,
pyridaZine, and triaZine, as well as substituted forms thereof.

alkoxy.

Z1 for example includes alkyl (for example butyl or pentyl),
cis-alkenyl; trans-alkenyl; substituted cis-alkenyl; substi
tuted trans-alkenyl; alkynyl (for example but-3-ynyl or pent

Z2 is selected from the group consisting of alkyl, substi

tuted alkyl, cycloalkyl, substituted cycloalkyl, alkenyl, sub
stituted alkenyl, alkynyl, substituted alkynyl, arylene, sub sti
tuted arylene, heterocycle, substituted heterocycle, alkoxy,

20

4-ynyl).
Z2 for example includes cis-alkenyl, trans-alkenyl, substi
tuted cis-alkenyl, and substituted trans-alkenyl.

and substituted alkoxy.
Z3 is selected from is selected from hydrogen, alkyl, sub

stituted alkyl, cycloalkyl, substituted cycloalkyl, alkenyl,

X‘ for example includes Cl‘, Br‘, I‘, N021 HSO4_, 804—,

sub stituted alkenyl, alkynyl, substituted alkynyl, aryl, sub sti
tuted aryl, heterocycle, and substituted heterocycle.

HPO4_, PO42“, ethanesulfonate, tri?uoromethane sulfate,
p-toluenesulfonate, benzenesulfonate, salicylate, proprion

25

ate, ascorbate, aspartate, fumarate, galactarate, maleate, cit
rate, glutamate, glycolate, lactate, malate, maleate, tartrate,

X‘ is an inorganic or organic anion.

For example, R1, R2, R3, R4, and R5 include hydrogen,
methyl, ethyl, propyl, butyl, tri?uoromethyl, pyrrolidine,
N-alkyl pyrrolidine (for example Where the alkyl chain is
methyl, ethyl or propyl), unsaturated pyrrolidine, unsaturated
N-alkyl pyrrolidine (for example Where the alkyl chain is
methyl, ethyl or propyl), aziridine, N-methyl aziridine, aze
tidine, N-methyl azetidine, unsaturated azetidine, unsatur

ated N-methyl azetidine, piperidine, N-methyl piperidine,
unsaturated piperidine, unsaturated N-methyl piperidine,

oxalate, succinate, or similar pharmaceutically acceptable
organic acid addition salts, including the pharmaceutically
30

acceptable salts listed in the Journal of Pharmaceutical Sci
ences volume 66, page 2, 1977, Which are hereby incorpo
rated by reference. The above salt forms may be in some cases
hydrates or solvates With alcohols and other solvents.

35

and A5 are carbon.

In a compound of Formula (I), preferably A1, A2, A3, A4,
In a compound of Formula (I), preferably R1 is hydrogen,
alkyl, or forms a six membered ring With A1, A2 and R2 and
with R1 and R2 providing four carbon atoms. More preferably,
R1 is selected from hydrogen, methyl, forms a six membered

azepane, N-methyl azepane, unsaturated azepane, unsatur
ated N-methyl azepane, azocane, N-methyl azocane, unsat
urated azocane, unsaturated N-methyl azocane, l-aza-bicy

clo[3.2.l]octane, l-aza-bicyclo[2.2.l]heptane, 8-methyl-8
aza-bicyclo[3 .2. l]octane, l-aza-tricyclo[3.3.1.13’7]decane,
methyl cycloalkyl, methyl substituted cycloalkyl, methylpyr

40

rolidine, methyl N-alkyl pyrrolidine (for example Where the

A2 and R2.
In a compound of Formula (I), preferably R2 is hydrogen,

alkyl chain is methyl, ethyl or propyl), methyl unsaturated

alkyl, aryl, 3-hydroxypropyl, l-methyl-2-pyrrolidinyl, halo,

pyrrolidine, methyl unsaturated N-alkyl pyrrolidine (for
example Where the alkyl chain is methyl, ethyl or propyl),

methyl aZiridine, methyl N-methyl aZiridine, methyl azeti
dine, methyl N-methyl azetidine, methyl unsaturated azeti
dine, methyl unsaturated N-methyl azetidine, methyl piperi
dine, methyl N-methyl piperidine, methyl unsaturated
piperidine, methyl unsaturated N-methyl piperidine, methyl

ring With A1, A2 and R2 and with R1 and R2 providing four
unsaturated carbon atoms, or forms a phenyl group With A1,

45

forms a six membered ring WithAl , A2 and R1 and with R1 and
R2 providing four carbon atoms, or forms a six membered

ring With A2, A3 and R3 and With R2 and R3 providing four
carbon atoms. More preferably, R2 is hydrogen, methyl, ethyl,

butyl, phenyl, 3-hydroxypropyl, l-methyl-2-pyrrolidinyl,

azepane, methyl N-methyl azepane, methyl unsaturated

bromo, forms a six membered ring With A1, A2 and R1 and
with R1 and R2 providing four unsaturated carbon atoms,

azepane, methyl unsaturated N-methyl azepane, methyl azo
cane, methyl N-methyl azocane, methyl unsaturated azocane,

bered ring With A2, A3 and R3 and With R2 and R3 providing

methyl unsaturated N-methyl azocane, methyl-l -aza-bicyclo
[3.2.1]octane, methyl-l-aza-bicyclo[2.2.l]heptane, 8-me
thyl-8-aza-bicyclo [3.2.1]octane, and methyl-l-aza-tricyclo

50

forms a phenyl group With A1, A2 and R1, forms a six mem

55

[3.3.1.13’7]decane.
As another example, when R1 and R2, or R2 and R3 together
With the carbons to Which they are attached, independently
form a three to eight-membered ring, that ring may be a

60

heterocycle containing up to three hetero atoms (for example
nitrogen, oxygen or sulfur) in the ring, and further may be

[c]thiophene, indole, indolenine, isoindole, cyclopental[b]
pyridine, pyrano[3,4-b]pynrole, indazole, indovaine,

In a compound of Formula (I), preferably R3 is hydrogen,
alkyl, or forms a six membered ring With A2, A3 and R2 and
With R2 and R3 providing four carbon atoms. More preferably,
R3 is hydrogen, methyl, forms a six membered ring With A2,
A3 and R2 and With R2 and R3 providing four unsaturated
carbon atoms, or forms a phenyl group With A2, A3 and R2.
In a compound of Formula (I), preferably R4 is hydrogen or

alkyl. More preferably, R4 is hydrogen or methyl.
In a compound of Formula (I), preferably R5 is hydrogen.

substituted With one or more substituents. For example, pos

sible rings include benzene, pyridine, pyran, indene, isoin

dene, benzofuran, isobenzofuran, benzo[b]thiophene, benzo

four unsaturated carbon atoms, or forms a phenyl group With
A2, A3 and R3 .

65

In a compound of Formula (I), preferably Z1 is absent, or is

alkyl, alkynyl, or alkoxy. More preferably, Z1 is absent, butyl,
but-3 -ynyl, pentyl, pent-4-ynyl or 2-ethoxy.

US 8,846,937 B2
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In a compound of Formula (I), preferably Z2 is alkyl, aryle
nyl or alkoxy. More preferably, Z2 is hexyl, octyl, dodecyl,
tridecyl, para-phenylene, or 2-ethoxy.
In a compound of Formula (I), preferably Z3 is alkyl, alky
nyl, aryl or heterocyclic. More preferably Z3 is propyl, butyl,
but- 1 -ynyl, hex-l -ynyl, phenyl, or 3 -pyridinyl.

is hydrogen, methyl, forms a six membered ring With A1, A2
and R2 and with R1 and R2 providing four unsaturated carbon
atoms, or forms a phenyl group With A1, A2 and R2; Wherein

R2 is hydrogen, methyl, ethyl, 3-hydroxypropyl, l-methyl-2
pyrrolidinyl, bromo, forms a six membered ring With A1, A2
and R1 and with R1 and R2 providing four unsaturated carbon
atoms, forms a phenyl group With A1, A2 and R1, forms a six
membered ring With A2, A3 and R3 and With R2 and R3 pro

In a compound of Formula (I), preferably X is a halogen.
More preferably, X is chloride, bromide or iodide.
In one embodiment, the compound of Formula (I) is
de?ned WhereinAl , A2, A3 , A4, andA5 are carbon; wherein R1

viding four unsaturated carbon atoms, or forms a phenyl

group With A2, A3 and R3; Wherein R3 is hydrogen, methyl,

is hydrogen, methyl, forms a six membered ring With A1, A2
and R2 and with R1 and R2 providing four unsaturated carbon

forms a six membered ring WlIhAZ, A3 and R2 and With R2 and
R3 providing four unsaturated carbon atoms, or forms a phe

atoms, or forms a phenyl group With A1, A2 and R2; Wherein

R2 is hydrogen, methyl, ethyl, butyl, phenyl, 3-hydroxypro
pyl, l-methyl-2-pyrrolidinyl, bromo, forms a six membered

ring With A1, A2 and R1 and with R1 and R2 providing four
unsaturated carbon atoms, forms a phenyl group With A1, A2
and R1, forms a six membered ring With A2, A3 and R3 and

15

With R2 and R3 providing four unsaturated carbon atoms, or

nyl group With A2, A3 and R2; Wherein R4 is hydrogen or
methyl; Wherein R5 is hydrogen; wherein Z1 is absent, butyl,
but-3-ynyl, pent-4-ynyl or 2-ethoxy; Wherein Z2 is hexyl,
octyl, dodecyl, tridecyl, para-phenylene, or 2-ethoxy;
Wherein Z3 is propyl, butyl, but-l-ynyl, hex-l-ynyl, phenyl,
or 3-pyridinyl; and Wherein X is chloride, bromide or iodide.

forms a phenyl group With A2, A3 and R3; Wherein R3 is 20
In another embodiment, the compound of Formula (I) is
hydrogen, methyl, forms a six membered ring With A2, A3 and
de?ned WhereinAl,A2,A3 , A4, and A5 are carbon; wherein R1
R2 and With R2 and R3 providing four unsaturated carbon
is hydrogen, methyl, or forms a phenyl group WlIhAl,A2 and

atoms, or forms a phenyl group With A2, A3 and R2; Wherein
R2; Wherein R2 is hydrogen, methyl, butyl, phenyl, l-methyl
R4 is hydrogen or methyl; Wherein R5 is hydrogen; Wherein
2-pyrrolidinyl, forms a phenyl group With A1, A2 and R1, or
Z1 is absent, butyl, but-3-ynyl, pentyl, pent-4-ynyl or 25 forms a phenyl group With A2, A3 and R3; Wherein R3 is
2-ethoxy; Wherein Z2 is hexyl, octyl, dodecyl, tridecyl, parahydrogen, methyl, or forms a phenyl group With A2, A3 and
phenylene, or 2-ethoxy; Wherein Z3 is propyl, butyl, but-lR2; Wherein R4 is hydrogen or methyl; Wherein R5 is hydro
ynyl, hex-l-ynyl, phenyl, or 3-pyridinyl; and Wherein X is
gen; wherein Z1 is pentyl or pent-4-ynyl; Wherein Z2 is para
chloride, bromide or iodide.
phenylene; Wherein Z3 is phenyl; and Wherein X is bromide.
In another embodiment, the compound of Formula (I) is
Exemplary compounds forthis application are presented in
de?ned WhereinAl,A2,A3 ,A4, andA5 are carbon; wherein R1
Table 1.
TABLE 1

R3
R4

R2

/ |
\@

H

N

21

R1

X9

I2

23/2
ID #

R1

R2

R3

R4

Z1

22

Z3

x

GZ—S 65A
GZ—565B
GZ—565C
GZ—566A
GZ—566B
GZ—566C

H
Me
H
H
H
Me

Me
H
H
Me
Me
H

H
H
Me
H
Me
Me

H
H
H
Me
H
H

but—3 —ynyl
but-3—ynyl
but-3—ynyl
but-3—ynyl
but-3—ynyl
but-3—ynyl

p-phenyl
p-phenyl
p-phenyl
p-phenyl
p-phenyl
p-phenyl

phenyl
phenyl
phenyl
phenyl
phenyl
phenyl

bromide
bromide
bromide
bromide
bromide
bromide

H
H
H

but-3—ynyl
but-3—ynyl
but-3—ynyl

p-phenyl
p-phenyl
p-phenyl

phenyl
phenyl
phenyl

bromide
bromide
bromide

butyl
H
H
phenyl
H
H
H
H
H
Me
H
H
H
H
H
H
Me
H
Me
H
Me
Me
Me
H
H
Me
H
phenyl With R2 phenyl with R1
H
H
H
phenyl With R3 phenyl With R2 H
H
l—methyl—Z—
H
H

but—3 —ynyl
but-3—ynyl
but-3—ynyl
butyl
butyl
butyl
butyl
butyl
butyl

p-phenyl
p-phenyl
p-phenyl
p-phenyl
p-phenyl
p-phenyl
p-phenyl
p-phenyl
p-phenyl

phenyl
phenyl
phenyl
phenyl
phenyl
phenyl
phenyl
phenyl
phenyl

bromide
bromide
bromide
bromide
bromide
bromide
bromide
bromide
bromide

butyl
butyl
butyl

p-phenyl
p-phenyl
p-phenyl

phenyl
phenyl
phenyl

bromide
bromide
bromide

butyl

p-phenyl

phenyl

bromide

GZ—567A
GZ—567B
GZ—567C

phenyl With R2 phenyl with R1
H
H
phenyl With R3 phenyl With R2
H
l—methyl—Z—
H

pyrrolidinyl
GZ—S 68A
GZ—568B
GZ—568C
GZ—573A
GZ—573B
GZ—573C
GZ—574A
GZ—574B
GZ—574C

GZ—575A
GZ—575B
GZ—575C

H
H
H
H
Me
H
H
H
Me

pyrrolidinyl
GZ—576A

H

butyl

H

H
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phenyl)-pent-4-ynyl]-pyridinium bromide; 2,4-dimethyl-1

nephrine, serotonin, gamma-aminobutryic acid, or glutamate.

[4- (4 -propyl -phenyl) -p ent-4 -ynyl] -pyridinium

Alternatively, the compound of Formula (I) may act as an

bromide;

2-[4-(4-propyl-phenyl)-pent-4-ynyl]-5,6,7,8-tetrahydro-iso
quinolinium bromide; 1-[5-(1,1'-biphenyl-4-yl)-pent-4

antagonist of nicotinic acetylcholine receptor function.

ynyl] -3 -(1-methyl-2 -pyrrolidinyl)-pyridinium

or duration of the release of a neurotransmitter from a central

Hence the compound of Formula (I) may decrease the extent

bromide;

1-[5-(1,1'-biphenyl-4-yl)-pentyl]-3-(1-methyl-2-pyrrolidi
nyl)-pyridinium bromide; 1-[2-(2-hexoxy-ethoxy)-ethyl]-3

nervous system tissue. The neurotransmitter affected may

methyl -pyridinium chloride; 1-[2-(2 -hexoxy-ethoxy)-ethyl] -

nobutryic acid, or glutamate.

4-methyl-pyridinium chloride; 1-[2-(2-hexoxy-ethoxy)
ethyl]-3,4-dimethyl-pyridinium chloride; 1-[2-(2-hexoxy
ethoxy)-ethyl]-3,5-dimethyl-pyridinium chloride; 1-[2-(2
hexoxy-ethoxy)-ethyl]-2-methyl-pyridinium chloride; 1-[2
(2-hexoxy-ethoxy)-ethyl] -2,4-dimethyl-pyridinium
chloride; 1-[2-(2-hexoxy-ethoxy)-ethyl] -5,6,7,8-tetrahydro
quinolinium chloride; 2-[2-(2-hexoxy-ethoxy)-ethyl]-5,6,7,
8-tetrahydro-isoquinolinium chloride; 1-[2-(2-hexoxy
ethoxy)-ethyl]-3-methyl-pyridinium chloride; 1-[2-(2
hexoxy-ethoxy)-ethyl]-3-methyl-pyridinium
chloride;
3 -methyl-1-[12-(3 -pyridinyl)-dodecyl] -pyridinium bromide;
4-methyl-1-[12-(3 -pyridinyl)-dodecyl] -pyridinium bromide;
3-bromo-1-[12-(3-pyridinyl)-dodecyl]-pyridinium bromide;

include dopamine, norepinephrine, serotonin, gamma-ami
Central nervous system disorders Which may be treated

according to the method of the present invention include

Alzheimer’s disease, dementia, cognitive dysfunctions (in
cluding disorders of attention, focus and concentration),
attention de?cit disorders, affective disorders, extrapyrami
5

20

3,4-dimethyl-1-[12-(3-pyridinyl)-dodecyl]-pyridinium bro

mide;

sive supramolecular palsy, Huntington’s disease, Gilles de la
Tourette syndrome, tardive dyskinesia, neuroendocrine dis
orders, dysregulation of food intake, disorders of nociception,
pain, mood and emotional disorders, depression, panic anxi
ety, psychosis, schizophrenia, or epilepsy.
In yet another embodiment, the present invention is
directed to a method for preventing and/ or treating sub stance
use and/or abuse comprising administering to a mammalian
subject in need thereof a therapeutically effective amount of a

3 ,5 -dimethyl-1-[12-(3 -pyridinyl) -dodecyl] -pyri

dinium bromide; and 3-(1-methyl-2-pyrrolidinyl)-1-[12-(3

pyridinyl) -dodecyl] -pyridinium bromide.

dal motor function disorders, Parkinson’s disease, progres

25

compound of Formula (I). In such a method, the compound of

The compounds of the present invention may contain one

Formula (I) may selectively bind to one or more subtypes of

or more stereocenters. The invention includes all possible
diastereomers and all enantiomeric forms as well as racemic

nicotinic acetylcholine receptor. The compound of Formula

mixtures. The compounds can be separated into substantially

tylcholine receptor function. Hence the compound of For

optically pure compounds.

(I) may act as an agoinst or partial agonist of nicotinic ace
30

The compounds of the invention are nicotinic acetylcholi

nereceptor agents. Thus, they may augment or inhibit[3 H]

neurotransmitter affected may include dopamine, norepi

nicotine binding, [3H]MLA binding, evoke or inhibit neu

nephrine, serotonin, gamma-aminobutryic acid, or glutamate.

rotransmitter release, and/or evoke or inhibit the ?ux of ions

through the nicotinic receptor.

35

In one embodiment, the present invention relates to a

method for selectively modulating the function of a nicotinic
acetylcholine receptor comprising administering to a mam
malian subject in need thereof a therapeutically effective
amount of a compound of Formula (I). In such a method, the

mula (I) may increase or prolong the release of a neurotrans
mitter from a central nervous system tissue. The

Alternatively, the compound of Formula (I) may act as an

antagonist of nicotinic acetylcholine receptor function.
Hence the compound of Formula (I) may decrease the extent
or duration of the release of a neurotransmitter from a central

nervous system tissue. The neurotransmitter affected may
40

include dopamine, norepinephrine, serotonin, gamma-ami
nobutryic acid, or glutamate.

compound of Formula (I) may selectively bind to one or more

subtypes of nicotinic acetylcholine receptor. The compound

The conditions of substance use and/or abuse treated

of Formula (I) may act as an agoinst or partial agonist of
nicotinic acetylcholine receptor function. Hence the com
pound of Formula (I) may increase or prolong the release of a

according to the method of the present invention include
nicotine abuse (including use in smoking cessation therapy),
45

neurotransmitter from a central nervous system tissue. The

amine abuse, cocaine abuse, or alcohol abuse.
In another embodiment, the present invention is directed to
a method for preventing and/or treating gastrointestinal tract
disorders comprising administering to a mammalian subject

neurotransmitter affected may include dopamine, norepi

nephrine, serotonin, gamma-aminobutryic acid, or glutamate.
Alternatively, the compound of Formula (I) may act as an

antagonist of nicotinic acetylcholine receptor function.

50

Hence the compound of Formula (I) may decrease the extent
or duration of the release of a neurotransmitter from a central

Formula (I) may selectively bind to one or more subtypes of

nicotinic acetylcholine receptor. The compound of Formula

include dopamine, norepinephrine, serotonin, gamma-ami
55

In another embodiment, the present invention is directed to

(I) may act as an agoinst or partial agonist of nicotinic ace

tylcholine receptor function. Hence the compound of For
mula (I) may increase or prolong the release of a neurotrans
mitter from a central nervous system tissue. The

a method for preventing and/or treating a central nervous

system associated disorder comprising administering to a
mammalian subject in need thereof a therapeutically effective
amount of a compound of Formula (I). In such a method, the

in need thereof a therapeutically effective amount of a com

pound of Formula (I). In such a method, the compound of

nervous system tissue. The neurotransmitter affected may

nobutryic acid, or glutamate.

nicotine intoxication, amphetamine abuse, methamphet

neurotransmitter affected may include dopamine, norepi
60

nephrine, serotonin, gamma-aminobutryic acid, or glutamate.

compound of Formula (I) may selectively bind to one or more

Alternatively, the compound of Formula (I) may act as an

subtypes of nicotinic acetylcholine receptor. The compound

antagonist of nicotinic acetylcholine receptor function.

of Formula (I) may act as an agoinst or partial agonist of
nicotinic acetylcholine receptor function. Hence the com
pound of Formula (I) may increase or prolong the release of a

or duration of the release of a neurotransmitter from a central

Hence the compound of Formula (I) may decrease the extent
65

nervous system tissue. The neurotransmitter affected may

neurotransmitter from a central nervous system tissue. The

include dopamine, norepinephrine, serotonin, gamma-ami

neurotransmitter affected may include dopamine, norepi

nobutryic acid, or glutamate.
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Gastrointestinal disorders which may be treated according
to the method of the present invention include irritable bowel

lulose, and/or polyvinylpyrrolidone (PVP). If desired, disin
tegrating agents may be added, such as the cross-linked poly

syndrome, colitis, diarrhea, constipation, gastric acid secre

vinyl pyrrolidone, agar, or alginic acid or a salt thereof such as

tion or ulcers.

sodium alginate. Also, wetting agents such as sodium dodecyl

The compounds of the present invention can be delivered

sulfate may be included.
Dragee cores are provided with suitable coatings. For this
purpose, concentrated sugar solutions may be used, which

directly or in pharmaceutical compositions along with suit
able carriers or excipients, as is well known in the art. For

example, a pharmaceutical composition of the invention may

may optionally contain gum arabic, talc, polyvinyl pyrroli
done, carbopol gel, polyethylene glycol, and/or titanium

include a conventional additive, such as a stabilizer, buffer,

salt, preservative, ?ller, ?avor enancer and the like, as known
to those skilled in the art. Exemplary buffers include phos

dioxide, lacquer solutions, and suitable organic solvents or
solvent mixtures. Dyestuffs or pigments may be added to the
tablets or dragee coatings for identi?cation or to characterize

phates, carbonates, citrates and the like. Exemplary preserva
tives include EDTA, EGTA, BHA, BHT and the like.

different combinations of active compound doses.
Pharmaceutical preparations for oral administration
include push-?t capsules made of gelatin, as well as soft,
sealed capsules made of gelatin and a plasticizer, such as
glycerol or sorbitol. The push-?t capsules can contain the
active ingredients in admixture with ?ller such as lactose,

An effective amount of such agents can readily be deter
mined by routine experimentation, as can the most effective
and convenient route of administration and the most appro

priate formulation. Various formulations and drug delivery
systems are available in the art. See, e. g., Gennaro, A. R., ed.

(1995) Remington’s Pharmaceutical Sciences.
Suitable routes of administration may, for example,

20

binders such as starches, and/or lubricants such as talc or

25

magnesium stearate and, optionally, stabilizers. In soft cap
sules, the active compounds may be dissolved or suspended in
suitable liquids, such as fatty oils, liquid paraf?n, or liquid
polyethylene glycols. In addition, stabilizers may be added.
All formulations for oral administration should be in dosages

include oral, rectal, transmucosal, nasal, or intestinal admin

istration and parenteral delivery, including intramuscular,
subcutaneous, intramedullary injections, as well as intrathe

cal, direct intraventricular, intravenous, intraperitoneal, intra
nasal, or intraocular injections. The agent or composition
thereof may be administered in a local rather than a systemic
manner. For example, a suitable agent can be delivered via

injection or in a targeted drug delivery system, such as a depot
or sustained release formulation.

The pharmaceutical compositions of the present invention

30

may be manufactured by any of the methods well-known in

suitable for such administration.
In one embodiment, the compounds of the present inven
tion can be administered transdermally, such as through a skin
patch, or topically. In one aspect, the transdermal or topical
formulations of the present invention can additionally com
prise one or multiple penetration enhancers or other effectors,

the art, such as by conventional mixing, dissolving, granulat

including agents that enhance migration of the delivered com

ing, dragee-making, levigating, emulsifying, encapsulating,

pound. Transderrnal or topical administration could be pre

entrapping, or lyophilizing processes. As noted above, the
compositions of the present invention can include one or

35

more physiologically acceptable carriers such as excipients
and auxiliaries that facilitate processing of active molecules
into preparations for pharmaceutical use.
Proper formulation is dependent upon the route of admin

istration chosen. For injection, for example, the composition
may be formulated in aqueous solutions, preferably in physi
ologically compatible buffers such as Hanks’ solution, Ring
er’ s solution, or physiological saline buffer. For transmucosal
or nasal administration, penetrants appropriate to the barrier
to be permeated are used in the formulation. Such penetrants
are generally known in the art. In a preferred embodiment of

ferred, for example, in situations in which location speci?c
delivery is desired.
For administration by inhalation, the compounds for use
according to the present invention are conveniently delivered
in the form of an aerosol spray presentation from pressurized
packs or a nebulizer, with the use of a suitable propellant, e. g.,

40

dichlorodi?uoromethane, trichloro?uoromethane, dichlo
rotetra?uoroethane, carbon dioxide, or any other suitable gas.
In the case of a pressurized aerosol, the appropriate dosage
unit may be determined by providing a valve to deliver a

metered amount. Capsules and cartridges of, for example,
45

gelatin, for use in an inhaler or insuf?ator may be formulated.

These typically contain a powder mix of the compound and a

the present invention, the present compounds are prepared in

suitable powder base such as lactose or starch.

a formulation intended for oral administration. For oral

Compositions formulated for parenteral administration by

administration, the compounds can be formulated readily by
combining the active compounds with pharmaceutically

injection, e. g., by bolus injection or continuous infusion can
50

acceptable carriers well known in the art. Such carriers enable
the compounds of the invention to be formulated as tablets,

pills, dragees, capsules, liquids, gels, syrups, slurries, suspen
sions and the like, for oral ingestion by a subject. The com
pounds may also be formulated in rectal compositions such as

55

Suspensions of the active compounds may also be prepared

as appropriate oily injection suspensions. Suitable lipophilic
60

solvents or vehicles include fatty oils such as sesame oil and

65

synthetic fatty acid esters, such as ethyl oleate or triglycer
ides, or liposomes. Aqueous injection suspensions may con
tain substances that increase the viscosity of the suspension,
such as sodium carboxymethyl cellulose, sorbitol, or dextran.
Optionally, the suspension may also contain suitable stabiliz

processing the mixture of granules, after adding suitable aux
iliaries, if desired, to obtain tablets or dragee cores. Suitable

excipients are, in particular, ?llers such as sugars, including
lactose, sucrose, mannitol, or sorbitol; cellulose preparations
such as, for example, maize starch, wheat starch, rice starch,

potato starch, gelatin, gum tragacanth, methyl cellulose,
hydroxypropylmethyl-cellulose, sodium carboxymethylcel

mulatory agents such as suspending, stabilizing and/or dis
persing agents. Formulations for parenteral administration
include aqueous solutions or other compositions in water
soluble form.

suppositories or retention enemas, e.g., containing conven
tional suppository bases such as cocoa butter or other glyc
erides.
Pharmaceutical preparations for oral use canbe obtained as

solid excipients, optionally grinding a resulting mixture, and

be presented in unit dosage form, e.g., in ampoules or in
multi-dose containers, with an added preservative. The com
positions may take such forms as suspensions, solutions, or
emulsions in oily or aqueous vehicles, and may contain for

ers or agents that increase the solubility of the compounds to

allow for the preparation of highly concentrated solutions.

US 8,846,937 B2
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Alternatively, the active ingredient may be in powder form for

toxic to therapeutic effects is the therapeutic index, which can

constitution with a suitable vehicle, e.g., sterile pyrogen-free

be expressed as the ratio LDSO/EDSO. Agents that exhibit high
therapeutic indices are preferred.

water, before use.

As mentioned above, the compositions of the present

Dosages preferably fall within a range of circulating con
centrations that includes the ED50 with little or no toxicity.

invention may also be formulated as a depot preparation.

Such long acting formulations may be administered by
implantation (for example, subcutaneously or intramuscu
larly) or by intramuscular injection. Thus, for example, the
present compounds may be formulated with suitable poly

Dosages may vary within this range depending upon the
dosage form employed and the route of administration uti
lized. The exact formulation, route of administration, and
dosage should be chosen, according to methods known in the
art, in view of the speci?cs of a subject’s condition.
The amount of agent or composition administered will, of
course, be dependent on a variety of factors, including the sex,

meric or hydrophobic materials (for example as an emulsion
in an acceptable oil) or ion exchange resins, or as sparingly
soluble derivatives, for example, as a sparingly soluble salt.

Suitable carriers for the hydrophobic molecules of the

age, and weight of the subject being treated, the severity of the

invention are well known in the art and include co-solvent

af?iction, the manner of administration, and the judgment of

systems comprising, for example, benzyl alcohol, a nonpolar

the prescribing physician.

surfactant, a water-miscible organic polymer, and an aqueous
phase. The co-solvent system may be the VPD co-solvent
system. VPD is a solution of 3% w/v benzyl alcohol, 8% w/v

of the nonpolar surfactant polysorbate 80, and 65% w/v poly
ethylene glycol 300, made up to volume in absolute ethanol.
The VPD co-solvent system (VPD15W) consists of VPD

The present compositions may, if desired, be presented in a
pack or dispenser device containing one or more unit dosage
forms containing the active ingredient. Such a pack or device
may, for example, comprise metal or plastic foil, such as a
20

diluted 1:1 with a 5% dextrose in water solution. This co

solvent system is effective in dissolving hydrophobic com

pounds and produces low toxicity upon systemic administra
tion. Naturally, the proportions of a co-solvent system may be

25

varied considerably without destroying its solubility and tox
icity characteristics. Furthermore, the identity of the co-sol

readily occur to those of ordinary skill in the art in view of the

vent components may be varied. For example, other low
toxicity nonpolar surfactants may be used instead of

polysorbate 80, the fraction size of polyethylene glycol may

disclosure herein, and are speci?cally contemplated.
30

EXAMPLES

35

The invention is further understood by reference to the
following examples, which are intended to be purely exem
plary of the invention. The present invention is not limited in
scope by the exempli?ed embodiments, which are intended as

be varied, other biocompatible polymers may replace poly
ethylene glycol, e. g., polyvinyl pyrrolidone, and other sugars
or polysaccharides may substitute for dextrose.

Alternatively, other delivery systems for hydrophobic mol
ecules may be employed. Liposomes and emulsions are well
known examples of delivery vehicles or carriers for hydro

illustrations of single aspects of the invention only. Any meth

phobic drugs. Liposomal delivery systems are discussed
above in the context of gene-delivery systems. Certain
organic solvents such as dimethylsulfoxide also may be

employed, although usually at the cost of greater toxicity.
Additionally, the compounds may be delivered using sus
tained-release systems, such as semi-permeable matrices of
solid hydrophobic polymers containing the effective amount
of the composition to be administered. Various sustained

40

release materials are established and available to those of skill

45

ods that are functionally equivalent are within the scope of the
invention. Various modi?cations of the invention in addition
to those described herein will become apparent to those
skilled in the art from the foregoing description. Such modi
?cations fall within the scope of the appended claims.

Example 1

in the art. Sustained-release capsules may, depending on their
chemical nature, release the compounds for a few weeks up to
over 100 days. Depending on the chemical nature and the

biological stability of the therapeutic reagent, additional
strategies for stabilization may be employed.

blister pack. The pack or dispenser device may be accompa
nied by instructions for administration. Compositions com
prising a compound of the invention formulated in a compat
ible pharmaceutical carrier may also be prepared, placed in an
appropriate container, and labeled for treatment of an indi
cated condition.
These and other embodiments of the present invention will

Synthesis of compound
2-methyl- 1 -(8 -phenyl-octyl)-pyridinium bromide

50

For any composition used in the present methods of treat
ment, a therapeutically effective dose can be estimated ini

tially using a variety of techniques well known in the art. For
example, in a cell culture assay, a dose can be formulated in
animal models to achieve a circulating concentration range

that includes the lC50 as determined in cell culture. Dosage
ranges appropriate for human subjects can be determined, for
example, using data obtained from cell culture assays and
other animal studies.
A therapeutically effective dose of an agent refers to that
amount of the agent that results in amelioration of symptoms
or a prolongation of survival in a subject. Toxicity and thera
peutic ef?cacy of such molecules can be determined by stan
dard pharmaceutical procedures in cell cultures or experi

mental animals, e. g., by determining the LD50 (the dose lethal
to 50% of the population) and the ED50 (the dose therapeuti
cally effective in 50% of the population). The dose ratio of

55

60

(8-Bromo-octyl)-benzene (1 mmol) was added to a solu

tion of 2-picoline (3 mmol) in acetonitrile, and the solution
65

mixture was re?uxed for 24 hours. The acetonitrile was

removed in a vacuum, and the resulting residue was parti
tioned between ether and water. The aqueous layer was
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washed extensively with ether until no picoline was left in the

(8-Bromo-octyl)-benzene (1 mmol) was added to a solu

aqueous layer. The resulting aqueous solution of the product

tion of 2,4-lutidine (3 mmol) in acetonitrile, and the solution

was extracted with chloroform. The chloroform was removed

re?uxed for 24 hours. The acetonitrile was removed in a

to afford the product (70%). lHNMR (300 MHZ, CDCl3,
ppm) 9.74 (d, 1H), 8.35 (m, 1H), 7.96 (m, 1H), 7.86 (d, 1H),
7.15-7.25 (m, 4H), 4.92 (t, 2H), 2.95 (s, 3H), 1.88-1.98 (m,
2H), 1.54-1.64 (m, 2H), 1.39-1.49 (m, 2H), 1.25-1.38 (br,

vacuum and the resulting residue was partitioned between
ether and water. The aqueous layer was washed extensively
with ether until no 2,4-lutidine was left in the aqueous layer.
The resulting aqueous solution of the product was extracted
with chloroform. The chloroform was removed to afford the

6H).

product (70%). lHNMR (300 MHZ, CDCl3, ppm), 9.50 (d,
1H), 7.70 (d, 1H), 7.60 (s, 1H), 7.10-7.30 (dd, 1H), 4.78 (t,
2H), 2.84 (s, 3H), 2.54-2.60 (m, 5H), 1.80-1.92 (m, 2H),
1.50-1.60 (br, 2H), 1.20-1.45 (br, 6H).

Example 2

Synthesis of Compound
3 -methyl- 1 - (8 -phenyl -octyl) -pyridinium bromide

Example 4

Synthesis of Compound
4-methyl- 1 -(8 -phenyl-octyl)-pyridinium bromide
20

| \

25

Br

UWW
30

tion of 3-picoline (3 mmol) in acetonitrile, and the solution

G)
N\

re?uxed for 24 hours. The acetonitrile was removed in a

uct (76%). lHNMR (300 MHZ, CDCl3, ppm) 9.40 (s, 1H),
9.22 (d, 1H), 8.02 (d, 1H), 7.96 (dd, 1H), 7.12-7.22 (dd, 4H),
4.94 (t, 2H), 2.62 (s, 3H), 2.56 (t, 2H), 1.94-2.04 (m, 2H),
1.50-1.60 (m, 2H), 1.20-1.40 (br, 8H). l3CNMR, 145.68,
144.65, 142.87, 142.37, 139.79, 128.55, 128.40, 127.89,
125.76, 62.20, 36.19, 32.29, 31.73, 29.53, 29.44, 29.33,
26.40,19.11.

Bre

35

(8-Bromo-octyl)-benzene (1 mmol) was added to a solu

tion of 4-picoline (3 mmol) in acetonitrile, and the solution
40

was re?uxed for 24 hours. The acetonitrile was removed in

45

vacuum and the resulting residue was partitioned between
ether and water. The aqueous layer was washed extensively
with ether until no picoline was left in the aqueous layer. The
resulting aqueous solution of the product was extracted with
chloroform. The chloroform was removed to afford the prod

Example 3

Synthesis of Compound
2,4-dimethyl-1 -(8 -phenyl-octyl)-pyridinium bromide

ACN,

re?ux
/

(8-Bromo-octyl)-benzene (1 mmol) was added to a solu

vacuum and the resulting residue was partitioned between
ether and water. The aqueous layer was washed extensively
with ether until no picoline was left in the aqueous layer. The
resulting aqueous solution of the product was extracted with
chloroform. The chloroform was removed to afford the prod

/
N

50

uct (78%). lHNMR (300 MHZ, CDCl3, ppm) 9.26 (d, 2H),
7.84 (d, 2H), 7.14-7.28 (dd, 4H), 4.90 (t, 2H), 2.62 (s, 3H),
2.56 (t, 2H), 1.92-2.02 (m, 2H), 1.50-1.60 (m, 2H), 1.20-1.40
(br, 8H). l3CNMR, 158.92, 144.28, 142.86, 128.95, 128.56,
128.40, 125.76, 61.61, 36.19, 32.15, 31.71, 29.53, 29.42,
29.31, 26.37, 22.63.

Example 5
55

Br

Synthesis of Compound
1-dodec-7-ynyl-2-methyl-pyridinium iodide

/

18—,
ACN,

re?ux

60

I
65

/

US 8,846,937 B2
21

22

-continued

-continued

/ |
G)
N\

¢

@

12-Chloro-dodec-5-yne (1 mmol) was mixed with potas
sium iodide (3 mmol) and 2-picoline (3 mmol) in butanone.

12-Chloro-dodec-5-yne (1 mmol) was mixed with potas
sium iodide (3 mmol) and 4-picoline (3 mmol) in butanone.

room temperature. The butanone was removed in a vacuum,

The mixture was re?uxed for 3 days and cooled to room
temperature, ?ltrated. The butanone was removed in a

and the resulting residue was partitioned between water and
ethyl ether. The aqueous layer was washed extensively with
ether until no 2-picoline was left in the aqueous layer. The
resulting aqueous solution of the product was extracted with
chloroform. The chloroform was removed to afford the prod

uct (85%). lHNMR (300 MHZ, CDCl3, ppm) 9.62 (d, 1H),
8.39 (dd, 1H), 7.99 (m, 1H), 7.91 (d, 1H), 4.88 (t, 2H), 2.97 (s,
3H), 2.12-2.20 m, 4H), 1.90-2.00 (m, 2H), 1.32-1.58 (m, 8H),
0.88 (t, 3H).

vacuum, and the resulting residue was partitioned between
water and ethyl ether. The aqueous layer was washed exten
sively with ether until no 4-picoline was left in the aqueous
layer. The resulting aqueous solution of the product was
extracted with chloroform. The chloroform was removed to

20

afford the product (87%). lHNMR (300 MHZ, CDCl3, ppm),
9.28 (d, 2H), 7.92 (d, 2H), 4.92 (t, 2H), 2.68 (s, 3H), 1.96-2.18
(m, 6H), 1.32-1.50 (br, 10H), 0.88 (t, 3H).

Example 6

Example 8

Synthesis of Compound
1-dodec-7-ynyl-3 -methyl-pyridinium iodide

1-dodec -7 -ynyl-2,4-dimethyl-pyridinium iodide

Synthesis of Compound
25

\

I

| \

/
N

30

W

Cl

N/

KI/Butanonc,
re?ux

/

N6
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12-Chloro-dodec-5-yne (1 mmol) was mixed with potas
sium iodide (3 mmol) and 3-picoline (3 mmol) in butanone.
The mixture was re?uxed for 3 days and cooled to room
temperature, ?ltrated. The butanone was removed in a

vacuum, and the resulting residue was partitioned between
water and ethyl ether. The aqueous layer was washed exten
sively with ether until no 3-picoline was left in the aqueous
layer. The resulting aqueous solution of the product was

40

Example 7

12-Chloro-dodec-5-yne (1 mmol) was mixed with potas
sium iodide (3 mmol) and 2,4-lutidine (3 mmol) in butanone.
The mixture was re?uxed for 3 days and cooled to room
temperature, ?ltrated. The butanone was removed in a

45

extracted with chloroform. The chloroform was removed to

afford the product (82%). lHNMR (300 MHZ, CDCl3, ppm)
9.36 (s, 1H), 9.18 (d, 1H), 8.24 (d, 1H), 8.00 (dd, 1H), 4.92 (t,
2H), 2.62 (s, 3H), 1.95-2.18 (m, 6H), 1.15-1.25 (br, 10H),
0.90 (t, 3H); l3CNMR, 145.51, 144.12, 144.78, 139.46,
127.56, 80.44, 79.42, 61.75, 31.72, 31.16, 28.65, 28.04,
25.52, 21.92, 18.75, 18.55, 18.40, 13.63.

vacuum, and the resulting residue was partitioned between
water and ethyl ether. The aqueous layer was washed exten
sively with ether until no 2,4-lutidine was left in the aqueous
layer. The resulting aqueous solution of the product was
extracted with chloroform. The chloroform was removed to

50

55

Synthesis of compound
1-dodec-7-ynyl-4-methyl-pyridinium iodide

afford the product (84%). lHNMR (300 MHZ, CDCl3, ppm),
9.40 (d, 1H), 7.75 (d, 1H), 7.66 (s, 1H), 4.78 (t, 3H), 2.88 (s,
3H), 2.60 (s, 3H), 2.05-2.15 (br, 4H), 1.80-2.00 (br, 2H),
1.30-1.50 (br, 10H), 0.86 (t, 3H); l3CNMR, 156.73, 153.05,
145.84, 136.61, 127.27, 80.86, 79.85, 58.12, 31.54, 30.94,
39.09, 26.17, 22.39, 22.30, 21.03, 18.96, 18.79, 14.02.
Example 9

Synthesis of Compound
1 -dodec -7 -ynyl-3, 5-dimethyl-pyridinium iodide
60

| \
Cl

W
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/

KI/Butanonc,
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/
W

Cl

N/

KI/Butanone,
re?ux
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Example 11

Synthesis of 1-dodec-9-ynyl-2-methyl-pyridinium
bromide

| \
/

12-Chloro-dodec-5-yne (1 mmol) was mixed with potas
sium iodide (3 mmol) and 3,5-lutidine (3 mmol) in butanone.

H3C

The mixture was re?uxed for 3 days and cooled to room
temperature, ?ltrated. The butanone was removed in vacuum,

and the resulting residue was partitioned between water and
ethyl ether. The aqueous layer was washed extensively with
ether until no 3,5-lutidine was left in the aqueous layer. The
resulting aqueous solution of the product was extracted with
chloroform. The chloroform was removed to afford the prod

uct (78%). lHNMR (300 MHZ, CDCl3, ppm), 9.06 (s, 2H),
8.00 (s, 1H), 4.86 (t, 3H), 2.48 (s, 3H), 1.98-2.16 (m, 6H),
1.32-1.48 (br, 10H), 0.88 (t, 3H); l3CNMR, 146.12, 141.38,
138.64, 80.43, 79.53, 61.46, 31.70, 31.17, 28.68, 28.07,
25.55, 21.92, 18.57, 18.42, 13.63.

m Br
—_

N

ACN, re?ux
N (9

H30

\ /
Bre

12-Bromo-dodec-3-yne (1 mmol) was added to a solution
20

of 2-picoline (3 mmol) in acetonitrile, and the solution was
re?uxed for 24 hours. The acetonitrile was removed in

25

vacuum, and the resulting residue was partitioned between
ether and water. The aqueous layer was washed extensively
with ether until no 2-picoline was left in the aqueous layer.
The resulting aqueous solution of the product was extracted
with chloroform. The chloroform was removed to afford the

product (70%). lHNMR (300 MHZ, CDCl3, ppm), 9.68 (d,
1H), 8.28 (m, 1H), 7.96 (m, 1H), 7.84 (d, 1H), 4.94 (t, 2H),

Example 10
30

2.98 (s, 3H), 2.05-2.20 (m, 4H), 1.88-2.00 (m, 2H), 1.20-1.60

(br, 10H), 1.10 (t, 3H).

Synthesis of Compound
1-dodec -7 -ynyl-3,4-dimethyl-pyridinium iodide

Example 12
35

Synthesis of Compound
1-dodec-9-ynyl-3-methyl-pyridinium bromide
Cl

W

/

40

N—,

\

KUButanonc,

Br
45

W

I N/

ACN,

re?ux

/

N@\ |
12-Chloro-dodec-5-yne (1 mmol) was mixed with Sodium

iodide (3 mmol) and 3,4-lutidine (3 mmol) in butanone. The
mixture was re?uxed for 3 days and cooled to room tempera
ture, ?ltrated. The butanone was removed in vacuum, and the

resulting residue was partitioned between water and ethyl
ether. The aqueous layer was washed extensively with ether
until no 3,4-lutidine was left in the aqueous layer. The result
ing aqueous solution of the product was extracted with chlo
roform. The chloroform was removed to afford the product

(72%). lHNMR, (300 MHZ, CDCl3, ppm, ppm), 9.22 (s, 1H),
9.04 (d, 1H), 7.80 (d, 1H), 4.84 (t, 3H), 2.52 (s, 3H), 2.50 (s,
3H), 1.92-2.14 (m, 6H), 1.28-1.45 (m, 10H), 0.84 (t, 3H).
l3CNMR, 157.84, 143.39, 141.81, 138.53, 128.72, 80.80,
79.90, 61.23, 32.03, 31.54, 29.08, 28.48, 25.91, 22.30, 20.78,
18.96, 18.79, 17.44, 14.02.

12-Bromo-dodec-3-yne (1 mmol) was added to a solution
55

60

65

of 3-picoline (3 mmol) in acetonitrile, and the solution was
re?uxed for 24 hours. The acetonitrile was removed in a

vacuum, and the resulting residue was partitioned between
ether and water. The aqueous layer was washed extensively
with ether until no picoline was left in the aqueous layer. The
resulting aqueous solution of the product was extracted with
chloroform. The chloroform was removed to afford the prod

uct (70%). lHNMR (300 MHZ, CDCl3, ppm), 9.42 (s, 1H),
9.24 (d, 1H), 8.24 (d, 1H), 8.00 (dd, 1H), 4.95 (t, 2H), 2.62 (s,
3H), 1.95-2.2 (m, 6H), 1.23-1.45 (br, 10H), 1.1 (t, 3H);
l3CNMR, 145.29, 144.24, 141.98, 139.42, 127.51, 81.57,
79.26, 61.83, 31.90, 28.95, 28.92, 28.82, 28.62, 26.02, 18.72,
18.63, 14.38, 12.40.

US 8,846,937 B2
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26

Example 13

1.89-1.98 (m, 2H), 1.78-1.86 (m, 2H), 1.51-1.59 (m, 2H),
1.27-1.37 (m, 2H), 0.91 (1, 1:7.2, 3H).

Synthesis of Compound
1-dodec-9-ynyl-4-methyl-pyridinium bromide

Example 15

Synthesis of Compound

1-[4-(4 -butyl-phenyl)-butyl]-3-methyl-pyridinium
bromide

I \

W

Br

10

\

N/

Br

AEN,
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15 \A/Q/W
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NACN,

re?ux
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20
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12-Bromo-dodec-3-yne (1 mmol) was added to a solution

of 4-picoline (3 mmol) in acetonitrile, and the solution was
re?uxed for 24 hours. The acetonitrile was removed in a 25

vacuum, and the resulting residue was partitioned between
ether and water. The aqueous layer was washed extensively
with ether until no picoline was left in the aqueous layer. The
resulting aqueous solution of the product was extracted with
chloroform. The chloroform was removed to afford the prod

solution re?uxed for 24 hours. The acetonitrile was removed

30

uct (82%). lHNMR (300 MHZ, CDCl3, ppm), 9.24 (d, 2H),
7.86 (d, 2H), 4.90 (t, 2H), 2.64 (s, 3H), 1.95-2.16 (m, 6H),
1.26-1.34 (br, 10H), 0.88 (t, 3H).
35

Example 14

Synthesis of
1 - [4 -(4-butyl-phenyl)-butyl] -2-methyl -pyridinium
bromide

1-(4-Bromo-butyl)-4-butyl-benzene (1 mmol) was added
to a solution of 3-picoline (3 mmol) in acetonitrile and the

40

in vacuum, and the resulting residue was partitioned between
ether and water. The aqueous layer was washed extensively
with ether until no picoline was left in the aqueous layer. The
resulting aqueous solution of the product was extracted with
chloroform. The chloroform was removed to afford the prod

uct (75%). lHNMR (300 MHZ, CDCl3, ppm), 9.32 (s, 1H),
9.2 (d, 1:5.1, 1H), 8.16 (d, 1:51, 7.91 (m, 1H), 7.07 (d, 1:8.4,
2H), 7.02 (d, 1:8.4, 2H), 4.96 (t, 1:7.2, 2H), 2.52-2.64 (m,
7H), 2.00-2.06 (m, 2H), 1.60-1.70 (m, 2H), 1.60-1.60 (m,
2H), 1.29-1.36 (m, 2H), 0.90 (t, 1:7.2, 3H); l3CNMR,
145.62, 144.71, 142.37, 140.84, 139.73, 138.32, 128.66,
128.48, 127.78, 61.82, 35.54, 34.95, 34.05, 31.71, 27.93,
22.72, 19.07, 14.33.

Example 16

Synthesis of Compound
45

1 - [4 -(4 -butyl -phenyl)-butyl] -4-methyl -pyridinium
bromide

MGM/Br

/
N

50

\

Br

I

/
N

1-(4-Bromo-butyl)-4-butyl-benZene (1 mmol) was added

55

to a solution of 2-picoline (3 mmol) in acetonitrile, and the
solution was re?uxed for 24 hours. The acetonitrile was

removed in a vacuum, and the resulting residue was parti
tioned between ether and water. The aqueous layer was 60
washed extensively with ether until no 2-picoline was left in

ACN,
re?ux

/ I
G)
N\
9
Br

the aqueous layer. The resulting aqueous solution of the prod
uct was extracted with chloroform. The chloroform was

removed to afford the product (74%). lHNMR (300 MHZ,
1-(4-Bromo-butyl)-4-butyl-benzene (1 mmol) was added
CDCl3, ppm), 9.69 (d, 1:6.6, 1H), 8.25-8.30 (m, 1H), 7.90 65 to a solution of 4-picoline (3 mmol) in acetonitrile, and the
solution was re?uxed for 24 hours. The acetonitrile was
7.95 (m, 1H), 7.77 (d, 1:7.8, 1H), 7.04-7.10 (m, 4H), 4.92 (t,

7.5, 2H), 2.84 (s, 3H), 2.66 (t, 1:7.2, 2H), 2.56 (t, 1:7.5, 2H),

removed in a vacuum, and the resulting residue was parti

US 8,846,937 B2
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tioned between ether and water. The aqueous layer was
washed extensively with ether until no picoline was left in the

nitrile was removed in a vacuum, and the resulting residue

aqueous layer. The resulting aqueous solution of the product

was partitioned between ether and water. The aqueous layer
was washed extensively with ether until no hydroxypropa

was extracted with chloroform. The chloroform was removed

nylpyridine was left in the aqueous layer. The resulting aque

to afford the product (72%). lHNMR (300 MHZ, CDCl3,
ppm), 9.22 (d, 1:6.6, 2H), 7.79 (d, 1:6.6, 2H), 7.05 (d, 1:8.4,
2H), 7.02 (d, 1:8.4, 2H), 4.90 (t, 1:7.5, 3H), 2.51-2.63 (m,
7H), 1.96-2.06 (m, 2H), 1.58-1.68 (m, 2H), 1.51-1.61 (m,

ous solution of the product was extracted with chloroform.

The chloroform was removed to afford the product (65%).

lHNMR (300 MHZ, CDCl3, ppm), 9.41 (s, 1H), 8.85 (d,
1:6.3, 1H), 8.26 (d, 1:8.1, 1H), 7.89 (dd, 1:63, 1:81, 1H),
7.02-7.07 (m, 4H), 4.90 (t, 1:7.5, 2H), 3.59 (t, 1:5.4, 2H),
3.00 (t, 1:6.9, 2H), 2.62 (t, 1:7.2, 2H), 2.55 (t, 1:7.8, 2H),
1.95-2.05 (m, 4H), 1.57-1.69 (m, 2H), 1.50-1.60 (m, 2H),
1.29-1.37 (m, 2H), 0.90 (t, 1:7.2, 3H).

2H), 1.31-1.37 (m, 2H), 0.89 (t, 1:7.2, 3H); l3CNMR,
158.91, 144.31, 140.83, 138.30, 128.92, 128.66, 128.45,
61.26, 35.54, 34.95, 34.04, 31.61, 27.95, 22.73, 22.57, 14.33.
Example 17

Example 19

Synthesis of 2-[4-(4-butyl-phenyl)-butyl]-5,6,7,8
tetrahydro-isoquinolinium bromide

Synthesis of Compound 1-[4-(4-butyl-phenyl)-bu
tyl] -2,4-dimethyl-pyridinium bromide
20

/

/

30

1-(4-Bromo-butyl)-4-butyl-benZene (1 mmol) was added
to a solution of tetrahydroisoquinoline (2 mmol) in acetoni
trile, and the solution was re?uxed for 24 hours. The aceto
nitrile was removed in vacuum, and the resulting residue was

partitioned between ether and water. The aqueous layer was
washed extensively with ether until no tetrahydroisoquino
line was left in the aqueous layer. The resulting aqueous
solution of the product was extracted with chloroform. The
chloroform was removed to afford the product (72%).

lHNMR (300 MHZ, CDCl3, ppm), 9.12 (s, 1H), 8.85 (d,
1:6.0, 1H), 7.61 (d, 1:6.0, 1H), 7.02-7.08 (m, 4H), 4.83 (t,
7.5, 3H), 2.92-2.94 (m, 4H), 2.61 (t, 1:7.5, 2H), 2.54 (t, 1:7.5,
2H), 1.90-2.04 (m, 2H), 1.80-1.90 (m, 4H), 1.62-1.69 (m,
2H), 1.53-1.62 (m, 2H), 1.29-1.37 (m, 2H), 0.90 (t, 1:7.2,
3H). 13CNMR, 157.94, 144.18, 140.82, 140.64. 138.96,
138.37, 128.65, 128.48, 127.99, 61.16, 35.54, 34.99, 34.05,
31.56, 29.92, 27.98, 26.69, 22.74, 21.37, 14.33.

35

1-(4-Bromo-butyl)-4-butyl-benzene (1 mmol) was added
40

45

aqueous layer. The resulting aqueous solution of the product
was extracted with chloroform. The chloroform was removed

50

to afford the product (79%). lHNMR (300 MHZ, CDCl3,
ppm), 9.51 (d, 1:6.2, 1H), 7.67 (d, 1:6.2, 1H), 7.54 (s, 1H),
7.05-7.07 (m, 4H), 4.83 (t, 1:7.2, 2H), 2.77 (s, 3H), 2.64 (t,
1:7.2, 2H), 2.52-2.58 (m, 5H), 1.87-1.92 (m, 2H), 1.76-1.82
(m, 2H), 1.50-1.58 (m, 2H), 1.29-1.37 (m, 2H), 0.91 (t, 1:7.8,

3H).
55

/

solution was re?uxed for 24 hours. The acetonitrile was

removed in a vacuum, and the resulting residue was parti
tioned between ether and water. The aqueous layer was
washed extensively with ether until no lutidine left in the

Example 18

Synthesis of 1-[4-(4-butyl-phenyl)-butyl]-3-(3 -hy
droxy-propyl) -pyridinium bromide

to a solution of 2,4-lutidine (3 mmol) in acetonitrile, and the

Example 20

OH

Synthesis of 1-[4-(4-butyl-phenyl)-butyl]-3,4-dim
ethyl-pyridinium bromide
60

OH

/ |

Br

1-(4-Bromo-butyl)-4-butyl-benZene (1 mmol) was added
to a solution of hydroxypropanylpyridine (2 mmol) in aceto
nitrile, and the solution was re?uxed for 24 hours. The aceto

65
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Example 22

Synthesis of Compound 1-[4-(4-butyl-phenyl)-but-3
ynyl] -3-methyl-pyridinium bromide

1-(4-Bromo-butyl)-4-butyl-benZene (1 mmol) was added
to a solution of 3,4-lutidine (3 mmol) in acetonitrile, and the
solution was re?uxed for 24 hours. The acetonitrile was

removed in a vacuum, and the resulting residue was parti
tioned between ether and water. The aqueous layer was
washed extensively with ether until no lutidine left in the

aqueous layer. The resulting aqueous solution of the product
was extracted with chloroform. The chloroform was removed

to afford the product (79%). lHNMR (300 MHZ, CDCl3,

ppm), 9.20 (s, 1H), 9.03 (d, 1:6.3, 1H), 7.72 (d, 1:6.3, 1H),
7.00-7.07 (m, 4H), 4.87 (t, 1:7.5, 2H), 2.60 (t, 1:7.8, 2H),
2.54 (t, 1:7.8, 2H), 2.49 (s, 3H), 2.46 (s, 3H), 1.99-2.04 (m,
2H), 1.50-1.66 (m, 4H), 1.28-1.36 (m, 2H), 0.90 (t, 1:7.5,
3H). l3CNMR 157.60, 143.56, 141.92, 140.78, 138.40,
128.63, 128.57, 128.47, 61.00, 35.54, 34.98, 34.04, 31.59,
27.96, 22.73, 20.66, 17.36, 14.31.

20

25

\\

1-(4-Bromo-but-1-ynyl)-4-butyl-benzene (1 mmol) was
added to a solution of 3-picoline (3 mmol) in acetonitrile, and
the solution was re?uxed for 24 hours. The acetonitrile was

Example 21
30

removed in a vacuum, and the resulting residue was parti
tioned between ether and water. The aqueous layer was
washed extensively with ether until no picoline was left in the

Synthesis of 1-[4-(4-butyl-phenyl)-butyl] -3,5-dim

aqueous layer. The resulting aqueous solution of the product

ethyl-pyridinium bromide

was extracted with chloroform. The chloroform was removed

to afford the product (77%). lHNMR R (300 MHZ, CDCl3,
35

/

MQMBI

40

ppm), 9.48 (s, 1H), 9.33 (d, 1:6.6, 1H), 8.24 (d, 1:7.2, 1H),
7.93 (dd, 1:66, 1:72, 1H), 7.16 (d, 1:8.2, 2H), 7.06 (d,
1:8.2, 2H), 5.21 (t, 1:6.0, 2H), 3.26 (t, 1:6.0, 2H), 2.59 (s,
3H), 2.56 (t, 2H), 1.49-1.59 (m 2H), 1.25-1.37 (m, 2H), 0.9 (t,
1:7.2, 3H); l3CNMR, 145.70, 144.78, 143.64, 142.26,
138.98,131.15,128.32, 126.94, 118.92, 85.84, 82.45, 59.90,
35.45, 33.28, 22.81. 22.24, 18.71, 13.89.

Example 23

Synthesis of Compound 1-[4-(4-butyl-phenyl)-but-3
ynyl] -4-methyl-pyridinium bromide
50

1-(4-Bromo-butyl)-4-butyl-benZene (1 mmol) was added
to a solution of 3,5-lutidine (3 mmol) in acetonitrile, and the
Br

solution was re?uxed for 24 hours. The acetonitrile was

removed in a vacuum, and the resulting residue was parti
tioned between ether and water. The aqueous layer was
washed extensively with ether until no lutidine was left in the

55

aqueous layer. The resulting aqueous solution of the product

/

was extracted with chloroform. The chloroform was removed 60

to afford the product (81%). lHNMR (300 MHZ, CDCl3,
ppm), 9.11 (s, 2H), 7.92 (s, 1H), 7.00-7.06 (m, 4H), 4.88 (t,
1:7.5, 2H), 2.51-2.62 (m, 7H), 1.99-2.05 (m, 2H), 1.49-1.66
(m, 4H), 1.28-1.35 (m, 2H), 0.89 (t, 1:7.2, 3H). l3CNMR,
146.17, 141.96, 140.81, 138.91, 138.40, 128.63, 128.48,
61.60, 35.54, 34.98, 34.05, 31.68, 27.95, 22.72, 18.88, 14.31.

\\
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1-(4-Bromo-but-1-ynyl)-4-butyl-benzene (1 mmol) was

-continued

added to a solution of 4-picoline (3 mmol) in acetonitrile, and

/

the solution was re?uxed for 24 hours. The acetonitrile was

removed in vacuum, and the resulting residue was partitioned
between ether and water. The aqueous layer was washed
extensively with ether until no picoline was left in the aqueous
layer. The resulting aqueous solution of the product was

5

@
N\

%
Bre

extracted with chloroform. The chloroform was removed to

afford the product (67%). lHNMR (300 MHZ, CDCl3, ppm),
9.40 (d, 1:6.9, 1H), 7.80 (d, 1H), 7.17 (d, 1:7.8, 2H), 7.06 (d,
1:7.8, 2H), 5.2 (t, 2H), 3.23 (t, 2H), 2.65 (s, 3H), 2.56 (t,
1:7.8, 2H), 1.49-1.57 (m, 2H), 1.27-1.35 (m, 2H), 0.90 (t,
1:7.5, 3H).

1-(4-Bromo-but-1-ynyl)-4-butyl-benzene (1 mmol) was
added to a solution of tetrahyroisoquinoline (2 mmol) in

Example 24

acetonitrile, and the solution was re?uxed for 24 hours. The
acetonitrile was removed in a vacuum, and the resulting resi
due was partitioned between ether and water. The aqueous

Synthesis of 1-[4-(4-butyl-phenyl)-but-3-ynyl]-3
ethyl-pyridinium bromide

layer was washed extensively with ether until no tetrahyroiso
quinoline was left in the aqueous layer. The resulting aqueous
solution of the product was extracted with chloroform. The
chloroform was removed to afford the product (68%).

lHNMR (300 MHZ, CDCl3, ppm), 9.30 (s, 1H), 9.04 (d,
1:6.3, 2H), 7.62 (d, 1:6.3, 1H), 7.18 (d, 1:8.4, 2H), 7.06 (d,
1:8.4, 2H), 5.10 (t, 1:60, 3.21 (t, 1:6.0, 2H), 2.94-2.96 (m,
2H), 2.56 (t, 1:8.1, 2H), 1.81-1.87 (m, 2H), 1.49-1.56 (m,
2H), 1.27-1.34 (m, 2H), 0.89 (t, 1:7.2, 3H); l3CNMR,
158.51, 144.59, 143.95, 140.93, 138.61, 131.55, 128.71,
127.57, 119.46, 85.97, 83.23, 59.58, 35.86, 33.69, 31.01,
26.70, 23.12, 22.63, 21.37, 14.28.
Example 26

Synthesis of 1-[4-(4-butyl-phenyl)-but-3 -ynyl]-3,4
dimethyl-pyridinium bromide
1-(4-Bromo-but-1-ynyl)-4-butyl-benzene (1 mmol) was
added to a solution of 3-ethylpyridine (3 mmol) in acetoni
trile, and the solution was re?uxed for 24 hours. The aceto
nitrile was removed in vacuum, and the resulting residue was

partitioned between ether and water. The aqueous layer was
washed extensively with ether until no ethylpyridine was left
in the aqueous layer. The resulting aqueous solution of the
product was extracted with chloroform. The chloroform was

removed to afford the product (67%). lHNMR (300 MHZ,

45

CDCl3, ppm), 9.43 (d, 1:6.0, 1H), 9.41 (s, 1H), 8.25 (d, 1:8.1,
1H), 7.96 (dd, 1:60, 1:81, 1H), 7.15 (d, 1:8.1, 2H), 7.06, d,
1:8.1, 2H), 5.26 (t, 1:6.0, 2H), 3.26 (t, 1:6.0, 2H), 2.90 (q,
1:7.5, 2H), 2.56 (t, 1:8.1, 2H), 1.49-1.59 (m, 2H), 1.27-1.37
(m, 5H), 0.90 (t, 1:7.2, 3H); l3CNMR, 144.65, 144.46,
144.14, 143.65, 142.45, 131.14, 128.30, 127.12, 118.87,
85.88, 82.45, 59.99, 35.45, 33.27, 26.01, 22.85, 22.21, 14.26,

1-(4-Bromo-but-1-ynyl)-4-butyl-benzene (1 mmol) was
added to a solution of 3-hydroypropanylpyridine (2 mmol) in

13.88.

Example 25

55

Synthesis of 2-[4-(4-butyl-phenyl)-but-3 -ynyl]-5,6,7,
8-tetrahydro -isoquinolinium bromide

layer was washed extensively with ether until no hydroypro
panylpyridine was left in the aqueous layer. The resulting
60

Br

/

acetonitrile, and the solution was re?uxed for 24 hours. The
acetonitrile was removed in a vacuum, and the resulting resi
due was partitioned between ether and water. The aqueous

I

%
65

aqueous solution of the product was extracted with chloro
form. The chloroform was removed to afford the product

(60%). lHNMR (300 MHZ, CDCl3, ppm), 9.39 (s, 1H), 9.13
(d, 1:6.3, 1H), 7.70 (d, 1:6.3, 1H), 7.17 (d, 1:8.1, 2H), 7.07
(d, 1:8.1, 2H), 5.13 (t, 1:6.0, 2H), 3.23 (t, 1:6.0, 2H), 2.57 (t,
1:7.8, 2H), 2.53 (s, 3H), 2.48 (s, 3H), 1.50-1.58 (m, 2H),
1.28-1.37 (m, 2H), 0.90 (t, 1:7.2, 3H); l3CNMR, 158.19,
143.98, 138.11, 131.53, 128.69, 128.05, 119.45, 83.11,
59.60, 35.84, 33.64, 23.12, 22.62, 20.77, 17.35, 14.23.

US 8,846,937 B2
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Example 27

-continued

Synthesis of 1-[4-(4-butyl-phenyl)-but-3-ynyl]-3,5-

\

dimethyl-pyridinium bromide

OH

I

5 N—QIi/M’a /
B19

\

1-(4-Bromo-but-1-ynyl)-4-butyl-benzene (1 mmol) was

I
B

10 added to a solution of 3-hydroypropanylpyridine (2 mmol) in

N

—

/

acetonitrile, and the solution was re?uxed for 24 hours. The

—>

I

.

ACN, r??uX

~

~

~

~

aceton1tr1le was removed 1n vacuum, and the result1ng residue

was partitioned between ether and water. The aqueous layer
15 was washed extensively with ether until no hydroypropa

l
_—

\

nylpyridine was left in the aqueous layer. The resulting aque
ous solution of the product was extracted with chloroform.

N® /

The chloroform was removed to afford the product (60%).

20 lHNMR (300 MHZ, CDCl3, ppm), 9.46 (s, 1H), 9.04 (d,
B16
1:6.0, 1H), 8.33 (d, 1:8.1, 1H), 7.92 (dd, 1:60, 1:81, 1H),
7.16 (d, 1:8.4, 2H), 7.04 (d, 1:8.1, 2H), 5.12 (t, 1:6.6, 2H),
1'(4'Br°m°'bm'1'Yny1)'4'bmy1'benzene (1 mmol) was
3.57 (t 6.0 2H) 3.22 (t 1:6.0 2H) 2.98 (t 1:7.2 2H) 2.54

added to a solution of 3,5-lutidine (2 mmol) in acetonitrile,

(t 1:7’5 33) 1’94 (p 60 2H), 1 47,4 570,11 2H), 1 2611 34

and the solution was re?uxed for 24 hours. The acetonitrile 25

’ 2H’ 0 8’9 ' t 1:7 ’ 3H ’_ i3CN'MR 1’45 5’4 '144 '99

was removed in a vacuum, and the resulting residue was

62 )’14i 83( ’1312'0’ 128x32 126 94" 11's 9’5 85'65’

washed extensively with ether until no lutidine was left in the
aqueous layer. The resulting aqueous solution of the product

82-43, 59-92, 59-78, 58-26, 35-44, 3328, 3233, 2924, 2258,
22.23, 18.39, 13.88.

partitioned between ether and water. The aqueous layer was

was extracted with chloroform. The chloroform was removed 30

to afford the product (80%). lHNMR (300 MHZ, coc13,

ppm), 9.39 (s, 1H), 9.13 (d, 1:6.3, 1H), 7.70 (d, 1:6.3, 1H),
7.17 (d, 1:8.1, 2H), 7.07 (d, 1:8.1, 2H), 5.13 (t, 1:6.0, 2H),
3.23 (t, 1:6.0, 2H), 2.57 (t, 1:7.8, 2H), 2.53 (s, 3H), 2.48 (s,
3H), 1.50-1.58 (m, 2H), 1.28-1.37 (m, 2H), 0.90 (t, 1:7.2,

Example 29

Synthesis ofcompound
3-methyl-1-(13-pyridin-3-yl-tridecyl)-pyridinium
bromide

| \
l

\

N/

Br

/
N

I

\
N/

N@ \
B re

I

/

3H); l3CNMR, 158.19, 143.98, 138.11, 131.53, 128.69, 50 3-(13-Bromo-tridecyl)-pyridine (1 mmol) was added to
128-05, 119-45, 83-11, 5950, 3584, 3354, 2312, 22-62,
3-picoline (5 ml), and the mixture was heated at 50 C over
20'77’ 1735’ 14'23'

night. The excess picoline was removed in vacuum, and the
resulting residue was partitioned between water and ether.
55 The aqueous layer was washed extensively with ether until no

Example 28

picoline left in the aqueous layer, and then the aqueous layer
Synthesis of 1-[4-(4-buty1-pheny1)-but-3-yny1]-3_(3_

hydroxy-propyl)-pyridinium bromide

OH

|
:

/ \/

<

>

1.58-1.60 (m, 2H), 1.20-1.36 (m, 16H); 13CNMR, 148.76,

Br N /

\/

was extracted with chloroform. The chloroform was removed

to afford the product (65%). lHNMR (300 MHZ, CDCl3,
60 ppm), 9.36 (s, 1H), 9.22 (d, 1:5.4, 1H), 8.44 (br, 2H), 8.21 (d,
1:75, 1H), 7.97 (m, 1H), 7.54 (d, 7.2, 1H), 7.24-7.24 m, 1H),
4.96 (t, 1:7.2, 2H), 2.58-2.65 M, 5H), 2.00-2.07 (m, 4H),

ACNW?HX

65 146.10, 145.58, 144.77, 142.38, 139.83, 137.29, 127.80,

123.98, 62.28, 58.71, 33.31, 32.36, 31.32, 29.80, 29.74,
29.64, 29.38, 29.35, 26.45, 1915,1881.

US 8,846,937 B2
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Example 30

Synthesis of Compound 3,4-dimethyl-1-(13 -pyridin
3 -yl-tridecyl)-pyridinium bromide

I \
I \

Br

N/

/
N

\
l /

N@\
I /

Br,

3-(13-Bromo-tridecyl)-pyridine (1 mmol) was added to
3,4-lutidine (5 ml), and the mixture was heated at 50 C over-

2.21 (br, 1H), 1.82-2.02 (m, 2H), 1.54-1.62 (m, 2H), 1.15
135 (by, 12H), l3CNMR3 157,61, 149.68, 146.92, 143.35,

night. The excess picoline was removed in a vacuum, and the 20 141 _91, 13845, 13833, 13632, 12855, 12357, 6137,

resulting residue was Partitioned between water and ether-

33.31, 32.19, 31.41, 29.85, 29.80, 29.68, 29.41, 26.45, 20.69,

The aqueous layer was washed extensively with ether until no
3,4-lutidine was left in the aqueous layer, and then the aque

17_ 40_

ous layer was extracted with chloroform. The chloroform was

removed to afford the product (60%). lHNMR (300 MHZ,
coc13, ppm), 9.23 (s, 1H), 9.04 (d, 1:6.3, 1H), 8.40 (br, 2H), 25

7.79 (d, 1:6.0, 1H), 7.48 (d, 8.1, 1H), 7.18-7.20 (m, 1H), 4.83
(t, 1:7.5, 2H), 2.58 (t, 1:7.5, 2H), 2.52 (s, 3H), 2.49 (s, 3H),

Example 31

Synthesis of Compound 3,5-dimethyl-1-(13-pyridin
3-yl-tridecyl)-pyridinium bromide

| \
I

\

Br

/

N

/
N

I

\

Na \

N/

B r9

I

/

40

3-(13-Bromo-tridecyl)-pyridine (1 mmol) was added to
3,5-lutidine (5 ml), and the mixture was heated at 50 C over
night. The excess picoline was removed in a vacuum, and the
resulting residue was partitioned between water and ether.
45 The aqueous layer was washed extensively with ether until no
3,5-lutidine was left in the aqueous layer, and then the aque
ous layer was extracted with chloroform. The chloroform was

removed to afford the product (62%). lHNMR (300 MHZ,

CDCl3, ppm), 9.10 (s, 2H), 8.45 (br, 2H), 7.96 (s, 1H), 7.57
(d, 1:7.5, 1H), 7.24-7.27 (m, 1H), 4.89 (t, 1:7.5, 2H), 2.59
50 2.54 (m, 8H), 1.99-2.04 (m, 2H), 1.57-1.62 (m, 2H), 1.21
1.38 (m, 18H), l3CNMR, 148.07, 146.11, 145.45, 141.94,
139.01, 137.96, 124.16, 62.13, 58.74, 33.29, 32.34, 31.26,
29.76, 29.73, 29.62, 29.39, 29.30, 26.49, 18.98, 18.82.
55

Example 32

Synthesis of Compound 2-(13-pyridin-3-yl-tridecyl)
5 ,6,7,8-tetrahydro -isoquinolinium bromide

US 8,846,937 B2
37
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Example 34

3-(13-Bromo-tridecyl)-pyridine (1 mmol) was added to
5,6,7,8-tetrahydro-isoquinoline (5 ml), and the mixture was

Synthesis of Compound

heated at 50 C overnight. The resulting residue was treated
with ether, and the ether was decanted after deposition for 30'.
The residue was partitioned between water and ether. The
aqueous layer was washed extensively with ether, and then
the aqueous layer was extracted with chloroform. The chlo
roform was removed to afford the product (62%). lHNMR

(300 MHZ, CDCl3, ppm), 9.22 (s, 1H), 8.90 (d, 1:6.3, 1H),
8.44 (br, 2H), 7.67 (d, 1:6.3, 1H), 7.55 (d, 8.1, 7.24-7.28 (m,
1H), 4.83 (t, 1:7.2, 2.98-3.01 (m, 4H), 2.60 (t, 1:7.8, 2H),
1.94-2.02 (m, 2H), 1.87-1.90 (m, 4H), 1.56-1.60 (m, 2H),
1.19-1.35 (br, 20H); l3CNMR, 157.87, 148.79, 146.13,
144.20, 140.68, 138.95, 138.80, 137.26, 128.08, 123.92,
61.40, 58.62, 33.30, 32.20, 31.34, 29.94, 29.82, 29.77, 29.67,

4-(5-bromo-pent-1-ynl)-1,1'-biphenyl

%

OH

20

%

Br

29.42, 29.36, 26.71, 26.46, 21.40, 18.81.
25

Example 33

Synthesis of Compound 5-(1,1'-biphenyl-4-yl)-pent

5-(1,1'-biphenyl-4-yl)-4-pentyn-1-ol (3 .40 g, 14.39 mmol)

4-yn-1-ol

30

and carbon tetrabromide (6.21 g, 18.71 mmol) were dissolved

in dry methylene chloride (20 mL) and cooled to 0° C. Triph

enyl phosphine (5.15 g, 19.65 mmol) in methylene chloride
(10 mL) was added dropwise, and the mixture was stirred for
1 h at 0° C. The mixture was poured into hexanes (100 mL),
and then ?ltered through a short silica gel column, washed

I Br

35

with ethylacetate/hexanes (1/4). The combined organic sol
vents were evaporated to dryness under reduced pressure. The

resulting residue was puri?ed by column chromatography
(hexanes:ethylacetate 30:1) to afford 4.20 g of the title com
40

%

OH

pound. Yield: 97%. 1H NMR (300 MHZ, CDCl3) 6 2.15 (m,
2H), 2.63 (t, 1:6.9 HZ, 2H), 3.60 (t, 1:6.3 HZ, 2H), 7.32-7.60
(m, 9H) ppm; 13C NMR (75 MHZ, CDC13) 6 18.5, 31.8, 32.8,
81.7, 88.8, 122.6, 127.0, 127.1, 127.6, 128.9, 132.1, 140.5,
140.6 ppm.

Example 35

Synthesis of Compound 1-[5-(1,1'-biphenyl-4-yl)
pent-4-ynyl] -2-methyl-pyridinium bromide
50

4-Bromobiphenyl (10.28 g, 44.10 mmol), 4-pentyn-1-ol
(4.45 g, 52.92 mmol), and bis(triphenylphosphine)palladium
(ll) dichloride (310 mg, 0.44 mmol) were stirred in triethy
lamine (100 mL) under nitrogen for 5 min. Copper(l) iodide
(42 mg, 0.22 mmol) was added, and the mixture was stirred
for 4 hrs at 65° C. The mixture was cooled to room tempera

ture and ?ltered through a celite pad, rinsed with ethylacetate.
The combined ?ltrate was evaporated to dryness under
reduced pressure. The resulting residue was puri?ed by col
umn chromatography (hexanes:ethylacetate 3:2) to afford
7.78 g ofthe title compound. Yield: 75%. 1H NMR (300 MHZ,

60

CDC13) 6 1.88 (m, 2H), 2.57 (t, 1:6.9 HZ, 2H), 3.84 (t, 1:6.0
HZ, 2H), 7.32-7.60 (m, 9H) ppm; 13C NMR (75 MHZ, CDC13)
6 16.4, 31.7, 62.1, 81.2, 90.2, 122.8, 127.0, 127.1, 127.6,

65

128.9, 132.0, 140.1 ppm.

